Clinical trial
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate…
NCT00132522 · EMD Serono, Industry · Completed
Key facts
| NCT number | NCT00132522 |
|---|---|
| Title | EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide |
| Official title | A Study to Find the Highest Dose of Biological Study Drug (EMD 273066) That Can Be Given Safely to Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-Small Cell Lung Cancers When First Given a Low Dose of Cyclophosphamide |
| Lead sponsor | EMD Serono, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer |
| Intervention type | Drug |
| Interventions | EMD 273066 |
| Enrollment | 45 |
| Start date | May 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Aug 22, 2005 |
| Last update posted | Oct 25, 2013 |
| Countries | Switzerland, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: